RSCM
OCUL icon

Rock Springs Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Rock Springs Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.77M Hold
383,716
– – 0.18% 77
2026
Q1 		$3.25M Buy
383,716
+37,896
+11% +$361K 0.19% 76
2025
Q4 		$4.2M Buy
345,820
+45,820
+15% +$557K 0.22% 76
2025
Q3 		$3.51M Buy
+300,000
New +$3.59M 0.2% 70

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Rock Springs Capital Management's OCUL Position: Q2 2026 in Review

Rock Springs Capital Management held its Ocular Therapeutix (OCUL) position steady in Q2 2026 at 383,716 shares worth $3.77M. The position accounts for 0.18% of the portfolio, ranked #77.

Rock Springs Capital Management first reported a position in OCUL in Q3 2025 and has held it in 4 quarters since. The position peaked at $4.2M in Q4 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Rock Springs Capital Management held 383,716 shares of Ocular Therapeutix worth $3.77M as of Q2 2026.
  • Rock Springs Capital Management left its Ocular Therapeutix share count unchanged in Q2 2026.
  • Ocular Therapeutix made up 0.18% of Rock Springs Capital Management's portfolio in Q2 2026, its #77 holding.
  • Rock Springs Capital Management first reported a position in Ocular Therapeutix in Q3 2025 and has held it in 4 quarters since.
  • Rock Springs Capital Management's Ocular Therapeutix position peaked at $4.2M in Q4 2025.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.